Bone Abstracts

Parathyroid hormone (PTH) is used to stimulate bone formation in osteoporotic patients, however concerns have been raised about the quality of the matrix produced since lower levels of total matrix mineral have been reported in osteoporotic and fracture patients treated with PTH. High resolution synchrotron-based Fourier Transform Infrared Microscopy (sFTIRM) was used to determine mineral content in age-matched bone during anabolic PTH treatment, using the simplified lamellar ...

Background: Cancer is one of the leading causes of death worldwide. Natural products have been regarded as important sources of potential chemotherapeutic agents. In this study, we evaluated the antiproliferative activity of oleuropein, an olive oil compound traditionally found in the Mediterranean diet.Design and Methods: The antiproliferative activity on two human osteosarcoma cell lines (MG-63 and Saos2) was evaluated in vitro using the MTT c...

Diabetes leads to development of osteoporosis. Experimental type 1 diabetes may be induced by a single dose of streptozotocin (STZ), and nicotinamide (NA) administered 15 min before STZ dose-dependently protects against the STZ action. Coffee drinking, apart of its health benefits, is taken into consideration as an osteoporosis risk factor. Data from human and experimental studies on coffee and caffeine effects on the skeletal system are inconsistent. For example, although oth...

Atypical femur fractures (AFF) have been associated with antiresorptive therapy. In a retrospective case-control study, we identified AFF using ASBMR 2013 criteria. Femoral shaft fractures were identified using ICD9 codes. We screened 1479 radiographs. Radiographs were excluded for high-energy trauma, tumor, or periprosthetic fracture. Two radiologists blinded to treatment scored 482 radiographs for AFF features, and jointly adjudicated discrepancies. The required AFF feature,...

Objectives: In XLH, FGF23-mediated hypophosphatemia leads to defective bone mineralization and rickets. Investigational product KRN23 binds FGF23 and inhibits its activity. The objective of this Phase 2 study was to evaluate the safety and efficacy of KRN23 in 52 children with XLH (ages 5–12 years, ≤Tanner 2).Methods: Patients were randomized to receive KRN23 biweekly (Q2W) or monthly (Q4W) by SC injection. KRN23 dose was titrated (maximum 2 m...

Objectives: In XLH, musculoskeletal outcomes of current treatment with oral phosphate (Pi)/active vitamin D are suboptimal for many patients. In a Phase 2, open-label study, we tested the hypothesis that KRN23 improves rickets and functional outcomes in XLH children.Methods: Fifty-two children with XLH (ages 5–12 years at baseline) received KRN23 subcutaneously biweekly (Q2W) or monthly (Q4W). At study entry, most participants had received oral Pi/a...

Objective: We evaluated the long-term efficacy of burosumab, a monoclonal antibody against FGF23, in a Phase 2 Study (NCT02163577) in children with XLH.Methods: Fifty-two children with XLH (5-12 years-old, Tanner ≤ 2) were randomized 1:1 to receive subcutaneous burosumab Q2W or Q4W for 64 weeks. Doses were titrated up to 2 mg/kg/dose targeting serum phosphorus levels within 1.1–1.6 mmol/l. All subjects entered the long-term extension at Week 6...

Objectives: X-linked hypophosphatemia (XLH) is a rare genetic disorder of phosphate metabolism caused by mutations in the PHEX gene. This pilot study aims to apply novel imaging techniques to asses the musculoskeletal phenotype of XLH patients by bidirectional axial transmission (BDAT) ultrasound, magnetic resonance spectroscopy (MRS) and high resolution peripheral quantitative computed tomography (HR-pQCT).Methods: BDAT bone ultrasound of the radius and...

Currently available osteoporosis treatment include antiresorptives and/or anabolic agents. Studies in animals have shown that beta-hydroxy-beta-methylbutyrate (HMB) administration affects anabolically bone tissue metabolism and improves morphological, densitometric and mechanical properties of bones in axial and appendicular skeleton. Thus, the aim of the study was to present first data on effects of 61-week treatment with HMB on volumetric bone mineral density (vBMD) of lumba...

Several environmental and genetic factors are determinant, also including sex, hormonal, ethnics, nutritional and lifestyle, may interferer on bone mass of children. However, the pediatric studies that approach the socioeconomic status and the quantitative ultrasound parameters (QUS) are scarce. The aim of this study was to compare the socioeconomic status on bone mass assessed by QUS in boys from 7 to 15 years old. In this cross-sectional study, were evaluated 520 Brazilian b...